when will eli lilly release retatrutide just released impressive study results for retatrutide, an investigational weight loss drug that targets three hormones—and may deliver more weight loss than current GLP-1s. See link below ⬇️ ADA 2026: Retatrutide Revolution

The FDA has approved Wegovy and Zepbound for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity

SALIENT FEATURES: Reduced Glutathione for enhanced efficacy and better results Sustained release formulation for enhanced patient compliance and safety Well tolerated, with a long-standing safety profile Vitamin C improves the bioavailability of glutathione Safe & effective treatment INDICATIONS Melasma Chloasma UV-Induced Hyperpigmentation Post Inflammatory Hyperpigmentation Dosage Twice a day Disclaimer: This information is for registered medical practitioner only

Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X, et al

Cheung, K